Regentis Biomaterials (RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage Repair

REGENTIS BIOMATERIALS LTD. (RGNT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update Advances GelrinC® U.S. pivotal trial with 43 patients treated; Completion of enrollment expected by approximately year end 2026 Expands European commercialization readiness,

Regentis Biomaterials (NYSE American: RGNT) priced a $6.5 million private placement with accredited and institutional investors at $3.50 per ordinary share, plus accompanying warrants (or $3.4999 per pre-funded warrant). The company will issue 1,857,143 shares (or pre-funded warrants) and warrants to buy 1,857,143 shares. Pre-funded warrants are exercisable at $0.0001; ordinary warrants at $4.20 for five years. Net proceeds will fund its GelrinC pivotal trial, FDA pre-market approval preparation

Regentis Biomaterials (NYSE: RGNT) shares moved sharply after the company filed a Form 6-K with the SEC, saying it requested withdrawal of its Form F-1 registration statement and decided not to pursue the related public offering. The stock rose 506.45% to $9.40 intraday, then fell 9.15% to $8.54 in after-hours.

Regentis (RGNT) shares rose 526.7% after it withdrew a planned SEC Form F-1 for a firm-commitment offering of 3.33M shares at an assumed $3.00. Cuprina (CUPR) jumped 111.8% after FDA clearance for MEDIFLY maggots for debridement of non-healing wounds. Intellia (NTLA) gained 23.2% on additional Phase 3 results for hereditary angioedema; it targets approval and a 1H 2027 launch.

Tesla began high-volume production of its electric Semi truck in Reno, Nevada, aiming for 1,000 trucks per week. The plant can produce up to 50,000 trucks annually. CEO Elon Musk announced a self-driving option is coming soon. Tesla has secured orders for 2,500 trucks from a shipper coalition, with deliveries starting Q4 2026. The Semi has a range of 325-500 miles and has undergone extensive testing.

Kodiak Sciences' stock rose 180% to $90.69 after its eye disease drugs, Zenkuda and tabirafusp alfa tedromer, met primary endpoints in a Phase 3 trial, showing non-inferior vision gains compared to Regeneron's Eylea. The company plans to seek FDA approval for Zenkuda in Q4 2026. Both drugs demonstrated favorable safety profiles and significant efficacy in treating wet age-related macular degeneration.